In the treatment of breast cancer, PI3K, mTOR Act kinase inhibitors are also used with increasing frequency; therefore, we compared the level of gene expression associated with the PI3K/Akt/mTOR pathway with and without mutations in breast cancer patients. Here, AKT1 is linked to breast cancer.